APAC Chronic Urticaria Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
APAC · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$704.0 MnPlaceholder estimate
Estimate 2025$771.5 Mn18.9% of the global market
Projected 2034$1.76 Bn 128.2%Adds $989.0 Mn over 9 forecast years
CAGR 2025–20349.6%Faster than 53% of 180 Pharmaceuticals markets here
Key players5
APAC is 18.9% of the global market.
Among regions, the largest is North America at $1.76 Bn.
Fastest growing: APAC (this report) at 9.6% a year.
APAC ranks 2nd of 6 by size among regions.
Market size projection
APAC
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
Value added each year
$989.0 Mn total, 2026–2034
Year-by-year market size, 2024–2034
Chronic Urticaria Treatment Market market size by year, APAC
Year
Market size
Change that year
Since 2025
2024 (estimate)
$704.0 Mn
—
—
2025 (base)
$771.5 Mn
+$67.6 Mn
—
2026 (forecast)
$845.6 Mn
+$74.1 Mn
+9.6%
2027 (forecast)
$926.8 Mn
+$81.2 Mn
+20.1%
2028 (forecast)
$1.02 Bn
+$89.0 Mn
+31.7%
2029 (forecast)
$1.11 Bn
+$97.5 Mn
+44.3%
2030 (forecast)
$1.22 Bn
+$106.9 Mn
+58.1%
2031 (forecast)
$1.34 Bn
+$117.1 Mn
+73.3%
2032 (forecast)
$1.47 Bn
+$128.4 Mn
+90%
2033 (forecast)
$1.61 Bn
+$140.7 Mn
+108.2%
2034 (forecast)
$1.76 Bn
+$154.2 Mn
+128.2%
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
Novartis AG, Sanofi, Regeneron Pharmaceuticals, Celldex Therapeutics, Roche (see all)
Active clinical trials
27 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The APAC Chronic Urticaria Treatment Market Analysis Executive Summary
Chronic urticaria treatments control long-lasting hives and itching that do not go away with standard antihistamines.
Key segments of the chronic Urticaria Treatment market include drug class (Antihistamines, Anti-IgE Biologics and BTK Inhibitors) and type (Chronic Spontaneous Urticaria and Chronic Inducible Urticaria).
Asia Pacific Chronic Urticaria Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
APAC Chronic Urticaria Treatment Market Dynamics
Market Growth Drivers
More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the chronic Urticaria Treatment market. Biosimilars are widening access.
Opportunity
New targets, oral drugs that replace injections and cell therapies for autoimmune disease give the chronic Urticaria Treatment market room to grow.
Market Restraints
High prices, infection risks with immune-suppressing drugs, patent expiries and the need for long-term treatment hold back the chronic Urticaria Treatment market.
Competitive Landscape for Chronic Urticaria Treatment Market in APAC
The chronic Urticaria Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Chronic Urticaria Treatment Market in APAC
Chronic Urticaria Treatment in APAC: rules, payment and research
In some of the countries we cover here, medicines are approved by TGA (Australia)[1], NMPA (China)[2], Drug Office (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], NPRA (Malaysia)[6], Medsafe (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9] and Thai FDA (Thailand)[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[11], basic medical insurance (China)[12], the Hospital Authority (Hong Kong)[13], Ayushman Bharat PM-JAY (India)[14], public health insurance (Japan)[15], subsidised public care (Malaysia)[16], Pharmac (New Zealand)[17], PhilHealth (Philippines)[18], MediShield Life (Singapore)[19] and the Universal Coverage Scheme (Thailand)[20]. ClinicalTrials.gov lists 27 studies on Chronic Urticaria Treatment that are recruiting, active or about to start in APAC.[21]
[21]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for chronic Urticaria Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Drug Class
4.2 By Type
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Novartis
7.2 Sanofi
7.3 Regeneron Pharmaceuticals
7.4 Celldex Therapeutics
7.5 Roche
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The chronic Urticaria Treatment market can be segmented based on various criteria, including drug class, type and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Chronic Urticaria Treatment right now, from free public sources.
Clinical trials
27 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan
Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Chronic Urticaria Treatment market in Asia Pacific?
Placeholder estimate: about $771.5 Mn in 2025, rising to about $1.76 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Chronic Urticaria Treatment market in Asia Pacific growing?
Placeholder estimate: about 9.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Chronic Urticaria Treatment market report cover?
The report splits the market by drug class (Antihistamines, Anti-IgE Biologics, BTK Inhibitors, Others), type (Chronic Spontaneous Urticaria, Chronic Inducible Urticaria) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Chronic Urticaria Treatment market?
Key players include Novartis AG, Sanofi, Regeneron Pharmaceuticals, Celldex Therapeutics and Roche.
What is driving the Chronic Urticaria Treatment market?
More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the chronic Urticaria Treatment market. Biosimilars are widening access.
How many clinical trials on Chronic Urticaria Treatment are running in Asia Pacific?
27 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Chronic Urticaria Treatment?
PubMed lists 677 papers on Chronic Urticaria Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
US
China
Canada
Japan
Germany
Brazil
France
UK
Italy
India
Spain
Ecuador
Saudi Arabia
Mexico
Australia
New Zealand
Russia
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Thailand
Singapore
Kenya